JP6657101B2 - 糖尿病及びそれから生じる疾患合併症の治療のための化合物 - Google Patents

糖尿病及びそれから生じる疾患合併症の治療のための化合物 Download PDF

Info

Publication number
JP6657101B2
JP6657101B2 JP2016551110A JP2016551110A JP6657101B2 JP 6657101 B2 JP6657101 B2 JP 6657101B2 JP 2016551110 A JP2016551110 A JP 2016551110A JP 2016551110 A JP2016551110 A JP 2016551110A JP 6657101 B2 JP6657101 B2 JP 6657101B2
Authority
JP
Japan
Prior art keywords
compound
alkyl
formula
represented
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016551110A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016535099A (ja
JP2016535099A5 (enExample
Inventor
プリエル、エッシャー
Original Assignee
ベン グリオン ユニバーシティ オブ ザ ネガフ リサーチ アンド ディベロップメント オーソリティ
ベン グリオン ユニバーシティ オブ ザ ネガフ リサーチ アンド ディベロップメント オーソリティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52117936&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6657101(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ベン グリオン ユニバーシティ オブ ザ ネガフ リサーチ アンド ディベロップメント オーソリティ, ベン グリオン ユニバーシティ オブ ザ ネガフ リサーチ アンド ディベロップメント オーソリティ filed Critical ベン グリオン ユニバーシティ オブ ザ ネガフ リサーチ アンド ディベロップメント オーソリティ
Publication of JP2016535099A publication Critical patent/JP2016535099A/ja
Publication of JP2016535099A5 publication Critical patent/JP2016535099A5/ja
Application granted granted Critical
Publication of JP6657101B2 publication Critical patent/JP6657101B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/50—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/055—Phenols the aromatic ring being substituted by halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/12—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings
    • C07C39/15—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings with all hydroxy groups on non-condensed rings, e.g. phenylphenol
    • C07C39/16—Bis-(hydroxyphenyl) alkanes; Tris-(hydroxyphenyl)alkanes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/24—Halogenated derivatives
    • C07C39/367—Halogenated derivatives polycyclic non-condensed, containing only six-membered aromatic rings as cyclic parts, e.g. halogenated poly-hydroxyphenylalkanes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/14—Unsaturated ethers
    • C07C43/178—Unsaturated ethers containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/50—Organo-phosphines
    • C07F9/5022—Aromatic phosphines (P-C aromatic linkage)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016551110A 2013-11-05 2014-11-04 糖尿病及びそれから生じる疾患合併症の治療のための化合物 Active JP6657101B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361900240P 2013-11-05 2013-11-05
US61/900,240 2013-11-05
PCT/IL2014/050959 WO2015068156A1 (en) 2013-11-05 2014-11-04 Compounds for the treatment of diabetes and disease complications arising from same

Publications (3)

Publication Number Publication Date
JP2016535099A JP2016535099A (ja) 2016-11-10
JP2016535099A5 JP2016535099A5 (enExample) 2017-12-14
JP6657101B2 true JP6657101B2 (ja) 2020-03-04

Family

ID=52117936

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016551110A Active JP6657101B2 (ja) 2013-11-05 2014-11-04 糖尿病及びそれから生じる疾患合併症の治療のための化合物

Country Status (14)

Country Link
US (1) US10111880B2 (enExample)
EP (1) EP3065723B1 (enExample)
JP (1) JP6657101B2 (enExample)
KR (1) KR20160094956A (enExample)
CN (1) CN106061940A (enExample)
AU (1) AU2014347668A1 (enExample)
CA (1) CA2928725A1 (enExample)
CL (1) CL2016001054A1 (enExample)
CR (1) CR20160207A (enExample)
EA (1) EA201690938A1 (enExample)
MX (1) MX2016005995A (enExample)
PH (1) PH12016500788A1 (enExample)
WO (1) WO2015068156A1 (enExample)
ZA (1) ZA201602888B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL257470B2 (en) * 2018-02-11 2023-12-01 Ben Gurion Univ Of The Negev Research And Development Authority Telomerase activator compounds for use in fertility and related applications
AU2018218003B2 (en) 2017-02-12 2024-02-08 Neuromagen Pharma Ltd. Telomerase activating compounds for use in fertility and related applications
WO2026058262A1 (en) * 2024-09-16 2026-03-19 Esther Priel Substituted tri-phenyl derivative compounds, compositions comprising same and applications of same

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4093557A (en) 1976-09-16 1978-06-06 Hercules Incorporated Process for inhibiting corrosion of metals in aqueous systems
AR240698A1 (es) 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
ATE186724T1 (de) 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
US4783495A (en) 1987-11-20 1988-11-08 Ciba-Geigy Corporation (Hydroxyphenyl) silane stabilizers
US4835202A (en) 1987-11-20 1989-05-30 Ciba-Geigy Corporation (Hydroxyphenyl) phosphine stabilized compositions
JPH02121941A (ja) 1988-10-28 1990-05-09 Teijin Chem Ltd ハロゲン化トリスフェニル誘導体および難燃性熱可塑性樹脂組成物
IE61928B1 (en) 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
JPH04268328A (ja) 1991-02-22 1992-09-24 Idemitsu Petrochem Co Ltd 分岐ポリカーボネート
JPH04328555A (ja) 1991-04-26 1992-11-17 Fuji Photo Film Co Ltd ポジ型フオトレジスト組成物
US5198531A (en) 1991-06-14 1993-03-30 Research Diagnostic Antibodies Polymeric resin for peptide synthesis
EP0567626B1 (en) 1991-11-19 2001-09-19 Amylin Pharmaceuticals, Inc. Amylin agonist peptides and uses therefor
WO1993015063A1 (en) 1992-02-03 1993-08-05 Hoechst Celanese Corporation Uv light stabilizing, antioxidant and colorant compounds
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
GB9218830D0 (en) 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
JP2845743B2 (ja) 1992-12-28 1999-01-13 三菱化学株式会社 新規なナフタレン誘導体
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
JP3026707B2 (ja) 1993-10-05 2000-03-27 出光石油化学株式会社 分岐状ポリカーボネートの製造方法
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
US6028103A (en) 1994-09-16 2000-02-22 Children's Medical Center Corporation Triaryl methane compounds and analogues thereof useful for the treatment or prevention of sickle cell disease or diseases characterized by abnormal cell proliferation
DE4439947A1 (de) 1994-11-09 1996-05-15 Boehringer Mannheim Gmbh 2,2-Dichloralkancarbonsäuren, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
US5571825A (en) 1995-03-31 1996-11-05 Warner-Lambert Company Method of selectively inhibiting prostaglandin G/H synthase-2
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
CZ293016B6 (cs) 1995-06-01 2004-01-14 Sankyo Company Limited Benzimidazolové deriváty a farmaceutické prostředky s jejich obsahem
US6297269B1 (en) 1995-06-06 2001-10-02 Pfizer Inc. Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors
GB9604242D0 (en) 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
US5889038A (en) 1996-03-20 1999-03-30 Children's Hospital Methods and products for treating diarrhea and scours: use of clotrimazole and related aromatic compounds
ATE314060T1 (de) 1996-03-20 2006-01-15 Harvard College Triarylmethanverbindungen zur behandlung von krebs, aktinischer keratose und kaposisarkom
US6191165B1 (en) 1996-05-31 2001-02-20 Allelix Neuroscience Inc. Pharmaceutical for treatment of neurological and neuropsychiatric disorders
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
DE122009000079I2 (de) 1996-08-30 2011-06-16 Novo Nordisk As Novo Alle Glp-1 derivate
JP4128247B2 (ja) 1996-11-01 2008-07-30 株式会社リコー フェノール系化合物及び電子写真感光体
JPH10153884A (ja) 1996-11-25 1998-06-09 Minolta Co Ltd 静電潜像現像用トナー
WO1998035033A1 (en) 1997-02-05 1998-08-13 1149336 Ontario Inc. Polynucleotides encoding proexendin, and methods and uses thereof
DE19711617A1 (de) * 1997-03-20 1998-09-24 Boehringer Mannheim Gmbh Neue Thiazolidindione, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
JP3728205B2 (ja) 1998-07-02 2005-12-21 マイクロリス・コーポレイション 固体表面を液状配合物で被覆する方法
FR2783246B1 (fr) 1998-09-11 2000-11-17 Aventis Pharma Sa Derives d'azetidine, leur preparation et les medicaments les contenant
DE19844547C2 (de) 1998-09-29 2002-11-07 Aventis Pharma Gmbh Polycyclische Dihydrothiazole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
KR100353014B1 (ko) 1998-11-11 2002-09-18 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
US6380378B1 (en) 1998-12-24 2002-04-30 Toagosei Company, Ltd. Nucleotide compound, nucleotide block oligonucleotide, and method for producing them
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
FR2789079B3 (fr) 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
US6417208B1 (en) 1999-02-05 2002-07-09 Albert Einstein College Of Medicine Of Yeshiva University Method of identification of inhibitors of PDE1C
JP4195145B2 (ja) 1999-04-01 2008-12-10 出光興産株式会社 ポリカーボネートの製造方法
US6262118B1 (en) 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
CA2647796A1 (en) 1999-07-28 2001-02-08 The Trustees Of The University Of Pennsylvania Method of inhibiting osteoclast activity
CA2383466C (en) 1999-09-16 2009-08-25 Tanabe Seiyaku Co., Ltd. Aromatic nitrogen-containing 6-membered cyclic compounds
TWI302149B (en) 1999-09-22 2008-10-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
AU7961800A (en) 1999-10-28 2001-05-08 Kyowa Hakko Kogyo Co. Ltd. Thiazolidinedione derivatives
SE9904413D0 (sv) 1999-12-03 1999-12-03 Astra Ab Comminuted form
CN1740182A (zh) 1999-12-22 2006-03-01 症变治疗公司 新的双氨基化膦酸酯前药
US6803375B1 (en) 2000-01-06 2004-10-12 The Regents Of The University Of California Non-peptide inhibition of T-lymphocyte activation and therapies related thereto
JP4187934B2 (ja) 2000-02-18 2008-11-26 富士フイルム株式会社 ポジ型レジスト組成物
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
HUP0300725A3 (en) 2000-08-11 2005-11-28 Pfizer Treatment of the insulin resistance syndrome with selective cgmp pde5 inhibitors
ATE512964T1 (de) 2000-10-12 2011-07-15 Cancer Rec Tech Ltd N8,n13-disubstituierte chinoä4,3,2,klüacridinium salze als arzneimittel
GB0031103D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
US20040132830A1 (en) 2001-01-19 2004-07-08 Finer Jeffrey T Triphenylmethane kinesin inhibitors
EP1355651A2 (en) 2001-02-02 2003-10-29 Pfizer Limited Treatment of diabetes mellitus using vardenafil
CN1543451A (zh) 2001-06-07 2004-11-03 过氧化物酶体增生剂激活的受体的调节剂
JP3909056B2 (ja) 2001-06-27 2007-04-25 スミスクライン ビーチャム コーポレーション ジペプチジルペプチダーゼ阻害剤としてのフルオロピロリジン類
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US6766960B2 (en) 2001-10-17 2004-07-27 Kilopass Technologies, Inc. Smart card having memory using a breakdown phenomena in an ultra-thin dielectric
US7045523B2 (en) 2001-10-18 2006-05-16 Novartis Ag Combination comprising N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and telomerase inhibitor
KR20040053210A (ko) 2001-11-02 2004-06-23 화이자 프로덕츠 인크. Ｐｄｅ9 억제제를 사용한 인슐린 저항 증후군 및 2형당뇨병의 치료
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
WO2003066814A2 (en) 2002-02-04 2003-08-14 Ceremedix, Inc. Peptide-dependent upregulation of telomerase expression
AU2003220342B2 (en) 2002-03-14 2007-06-07 Bayer Pharmaceuticals Corporation Methods of treating diabetes using PDE 11A inhibitors
CA2519357A1 (en) 2003-03-17 2004-09-30 Pfizer Products Inc. Treatment of type 1 diabetes with pde5 inhibitors
US20040220186A1 (en) 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
JP4517723B2 (ja) 2003-05-22 2010-08-04 住友ベークライト株式会社 ナフトキノンジアジドスルホン酸エステル、それを用いたポジ型感光性樹脂組成物、半導体装置及び表示素子
AP2280A (en) 2003-06-23 2011-10-31 Geron Corp Compositions and methods for increasing telomeraseactivity.
MXPA05013553A (es) 2003-06-30 2006-03-09 Altana Pharma Ag Pirrolodihidroisoquinolinas como inhibidores de pde10.
EP1651251A4 (en) 2003-07-31 2008-06-18 Bayer Pharmaceuticals Corp METHOD FOR THE TREATMENT OF DIABETES AND RELATED DISEASES USING PDE 10A INHIBITORS
US20050049208A1 (en) * 2003-09-03 2005-03-03 Kaufmann Doug A. Method of treating and method of preventing diabetes
CN102079743B (zh) 2004-03-15 2020-08-25 武田药品工业株式会社 二肽基肽酶抑制剂
BRPI0511854A (pt) 2004-06-07 2008-01-15 Pfizer Prod Inc inibição de fosfodiestearase 10 como tratamento para condições relacionados com a obesidade e relacionadas a sìndrome metabólica
WO2006007864A1 (en) 2004-07-17 2006-01-26 Max Planck Geselllschaft Zur Förderung Der Wissenschaft Treating neurodegenerative conditions
JP4929569B2 (ja) 2004-08-20 2012-05-09 東レ株式会社 高分子電解質材、ならびにそれを用いた高分子電解質膜、膜電極複合体および高分子電解質型燃料電池
EP2305246B1 (en) 2005-01-31 2015-08-26 The Trustees of the University of Pennsylvania Tumor necrosis factor inhibitors
WO2006084031A1 (en) 2005-02-01 2006-08-10 Icagen, Inc. Imines as ion channel modulators
JP5211438B2 (ja) 2005-06-09 2013-06-12 東レ株式会社 樹脂組成物およびそれを用いた表示装置
PT2152663E (pt) * 2007-06-04 2014-06-03 Univ Ben Gurion Compostos de triarilo e composições que compreendem os mesmos

Also Published As

Publication number Publication date
EP3065723A1 (en) 2016-09-14
US20160263124A1 (en) 2016-09-15
CN106061940A (zh) 2016-10-26
JP2016535099A (ja) 2016-11-10
CR20160207A (es) 2016-08-10
MX2016005995A (es) 2016-08-17
EP3065723B1 (en) 2020-09-23
AU2014347668A1 (en) 2016-05-19
EA201690938A1 (ru) 2016-11-30
PH12016500788A1 (en) 2016-06-13
KR20160094956A (ko) 2016-08-10
CL2016001054A1 (es) 2016-12-02
US10111880B2 (en) 2018-10-30
CA2928725A1 (en) 2015-05-14
WO2015068156A1 (en) 2015-05-14
ZA201602888B (en) 2019-04-24

Similar Documents

Publication Publication Date Title
US20090317372A1 (en) Small molecules for the reduction of high blood glucose level
EP2637664B1 (en) Compositions and methods of treating pulmonary hypertension
EP2579879B1 (en) Triazine derivatives for delaying the onset of type 1 diabetes
ES2878001T3 (es) Composiciones del activador de la glucocinasa para el tratamiento de la diabetes
JP2005533775A (ja) 糖尿病を処置するための組成物および方法
JP2024545887A5 (enExample)
US9907767B2 (en) Pharmaceutical compositions and the treatment of overactive bladder
CN111246859B (zh) 含有锌盐、环二肽-组氨酸脯氨酸及作为有效成分的抗糖尿药物的糖尿病预防或治疗用药学组合物
US20150258107A1 (en) Methods and compositions for treating depression
EP3065723B1 (en) Compounds for the treatment of diabetes and disease complications arising from same
US20150258112A1 (en) Methods and compositions for treating depression using ibogaine
JP6412241B2 (ja) 肝機能改善法
US20150125546A1 (en) Combination therapy for treating pulmonary hypertension
CA3088178A1 (en) Treatment of liver diseases
US9468669B2 (en) Methods to treat dysregulated blood glucose disorders
RU2646475C2 (ru) Лечение диабета I и II типа
JP2021520403A (ja) 糖尿病予防・治療用の医薬品組成物及びその用途
HK1230579A1 (en) Compounds for the treatment of diabetes and disease complications arising from same
WO2022061962A1 (zh) 一种l型氨基酸转运蛋白抑制剂或拮抗剂有效干预糖尿病的方法
JP2022523303A (ja) グルコース代謝障害の長時間作用型の予防または治療に使用するためのβ－ラクタム化合物またはその塩
WO2025152110A1 (zh) 用于阿尔兹海默症治疗的联合用药及其药物组合物
WO2023165479A1 (zh) 硝酮化合物或其在药学上可接受的盐与sglt-2抑制剂联合应用
TW202610632A (zh) 抗過量給藥的組合物及其用途
KR20250158762A (ko) 고혈당증 치료에서의 용도를 위한 베타-2-아드레날린 수용체 작용제 및 glp-1 수용체 작용제의 조합
KR20250129797A (ko) 글루코오스 수치를 조절하기 위한 조성물 및 방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171101

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171101

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180731

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180727

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190520

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190717

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190816

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191015

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191213

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200107

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200205

R150 Certificate of patent or registration of utility model

Ref document number: 6657101

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250